(Q36006851)

11 August 2017

1 reference

title

Pharmacokinetics of pegylated interferons: what is misleading? (English)

1 reference

11 August 2017

1 reference

Paolo Caliceti

1

1 reference

11 August 2017

publication date

1 November 2004

1 reference

Digestive and Liver Disease

11 August 2017

published in

1 reference

11 August 2017

volume

36 Suppl 3

1 reference

11 August 2017

page(s)

S334-9

1 reference

Clinical Pharmacokinetics of Interferons

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Viral kinetics in hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Management of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Pegylated interferons for the treatment of chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Pegylation: a novel process for modifying pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Structural and biologic characterization of pegylated recombinant IFN-alpha2b

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

A branched monomethoxypoly(ethylene glycol) for protein modification

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Development of pegylated interferons for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Side effects of therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Localization of hepatitis C virus in gastrointestinal mucosa: a possible reservoir for relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Detection of extrahepatic hepatitis C virus replication by a novel, highly sensitive, single-tube nested polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Molecular evidence that the hepatitis C virus replicates in the oral mucosa.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Hepatitis C virus may infect extrahepatic tissues in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD).

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2804%2980002-1

7 January 2021

10.1016/S1590-8658(04)80002-1

Identifiers

DOI

1 reference

11 August 2017

1 reference